NCIt definition : An orally bioavailable heterobifunctional protein degrader of bromodomain-containing
protein 9 (BRD9; sarcoma antigen NY-SAR-29; rhabdomyosarcoma antigen MU-RMS-40.8),
with potential antineoplastic activity. Sendegobresib is comprised of an E3 ligase-binding
moiety and a BRD9-binding moiety. Upon oral administration, sendegobresib targets
and binds to BRD9 with its BRD9-binding moiety. Upon BRD9 binding, the E3 ligase-binding
moiety binds to cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase
complex, which directs proteins for destruction, resulting in the proteasome-mediated
degradation of BRD9. This leads to an inhibition of the growth of tumor cells that
rely on BRD9 for survival. BRD9, a component of one form of the Brg/Brahma-Associated
Factor (BAF) complex, is needed for the survival of certain cancer cells due to mutations.;